Varicella-zoster virus infection: natural history, clinical manifestations, immunity and current and future vaccination strategies by Freer, Giulia & Pistello, Mauro
REVIEW
New Microbiologica, 41, 2, 95-105, 2018, ISN 1121-7138
Varicella-zoster virus infection: natural history,  
clinical manifestations, immunity and current  
and future vaccination strategies
Giulia Freer1, Mauro Pistello1,2
1Retrovirus Center and Virology Section, Department of Translational Research and New Technologies in Medicine and Surgery,  
University of Pisa, Italy; 2Virology Unit, Pisa University Hospital, Pisa, Italy
INTRODUCTION
Varicella-zoster virus (VZV) belongs to the Herpesviridae, 
large enveloped viruses with an icosahedral capsid and 
a double-stranded DNA genome. Herpesviruses are very 
common among mammals: eight have been identified in 
man and are transmitted in different ways from the earli-
est stages of life. Because of this, about 80% of the adult 
population has antibodies to most, if not all, human her-
pesviruses, apart from the human herpesvirus-8 that is 
less prevalent especially in Western countries (Abendroth 
et al., 2010; Levin et al., 2016).
Herpesviruses exhibit an extraordinary ability to induce 
persistent infections. The ways these viruses remain indef-
initely in the infected individual differ. The α-herpesvirus 
subfamily, that includes herpes simplex virus (HSV) type-1 
and -2, in addition to VZV, persists in nervous tissue. In 
neurons, α-herpesviruses have developed a sophisticated 
way of interacting with the expression of specific genes to 
maintain latency, absence of viral protein production, and 
the expression of microRNA and other viral factors that 
effectively counteract the host’s defenses. Latency is alert, 
not passive, and directly managed by the virus that under 
conditions of cell suffering, upon endogenous and exoge-
nous stimuli or changes in the immune status, turns off 
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latency-related genes to reactivate those that lead to viral 
replication (Baines and Pellets 2007; Baird et al., 2013; Ger-
shon et al., 2012; Kennedy et al., 2015; Zerboni et al., 2014).
VZV causes two different diseases during primary infec-
tion and reactivation: the first, varicella, typically occurs 
during childhood and is the consequence of exogenous in-
fection by VZV, the second is zoster, which occurs due to 
reactivation of the latent virus many years, even dozens, 
after primary infection (Galetta et al., 2015).
This article will briefly describe the natural history and 
pathophysiology of VZV infection, diagnosis and therapy 
and its epidemiology prior to the introduction of vaccina-
tion. In addition, current and future vaccination options 
to protect against primary infection and reactivation will 
be discussed.
Natural history and pathophysiology of VZV infection
Chickenpox, or varicella, is a pandemic, highly contagious 
rash illness transmitted by inhalation of saliva droplets 
dispersed in the air by subjects with acute infection or, 
rarely, by direct contact with skin lesions of subjects with 
varicella or zoster.
Because of the absence of a suitable animal model, the 
natural history of infection is not clearly understood. In 
the most accepted model, VZV at entry gives rise to a short 
local replication in the upper respiratory tract, in epithe-
lial cells and the tonsils (Ku et al., 2004). In these sites, it 
infects T cells and gives rise to a subclinical cell-associat-
ed viremia about 4-6 days after infection. During viremia, 
the virus is disseminated to reticuloendothelial tissues, in-
cluding liver and spleen, where it further multiplies. VZV 
is eventually transported to the skin and mucous mem-
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SUMMARY
Varicella-zoster virus (VZV) is the etiologic agent of varicella (chicken pox), a childhood exanthematic 
disease that develops as a result of primary infection, and zoster (shingles), caused by reactivation of 
the virus persisting in a latent form in the dorsal sensory ganglia. Although varicella is generally a mild 
self-limiting illness, in immunocompromised subjects and adults it can have a serious clinical course that 
can lead to permanent damage of the central nervous system. In these and in most zoster cases, treatment 
with anti-herpetic drugs and/or immunotherapy is necessary.
Because it is highly contagious, varicella is one of the most common exanthematic diseases. It is prevent-
able by vaccination with an attenuated vaccine administered around the first year of age, and with a boost 
vaccination in school age.
This article briefly describes the natural history and pathophysiology of VZV infection and its current 
epidemiology and provides an overview of current and future vaccine options to protect against varicella 
and/or zoster.
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branes with a second viremic phase occurring about 14 
days after infection (Figure 1) (Abendroth et al., 2010; Hei-
ninger and Seward, 2006). Memory T cells seem to have a 
significant role in promoting viral replication in epithelial 
cells during which viral gene products downregulate the 
IFN-α response mounted by adjacent epidermal cells (Zer-
boni et al., 2014). Once the antiviral response is overcome, 
viral replication in infected keratinocytes and ensuing cell 
damage and inflammatory and immunes response cause 
the formation of vesicles filled with virions. The resulting 
skin rash (exanthema) shows up about two weeks (10-21 
days) after infection (Ku et al., 2004). Contagiousness is 
maximum 1-2 days before the onset of a rash, when the 
virus spreads by droplets and aerosols from the nasophar-
ynx, during the first 5-7 days after the appearance of rash 
(Abendroth et al., 2010; Gershon et al., 2015; Heininger 
and Seward, 2006; Ouwendijk et al., 2015).
The rash involves maximally the trunk, with small pruritic 
maculopapular vesicles that spread to the neck and limbs. 
After 12 to 72 hours the lesions turn into pustules (simi-
lar to vesicles but containing purulent material) that often 
break down giving rise to scabs. Lesions do not all appear 
and evolve into scabs at the same time, but rather appear 
in waves, also involving the mucous membranes, especial-
ly in the oral cavity and tonsillar area. The pustules usu-
ally heal without leaving sequelae but, if scratched, they 
can become infected by staphylococci and streptococci 
and leave a permanent scar. The asynchrony of lesion ap-
pearance and their poor diffusion at the distal extremities 
of the limbs were distinctive features from smallpox rash. 
As scabs form and fall off, contagiousness gradually de-
creases.
Varicella rash is preceded by prodromal symptoms, such 
as generalized malaise, nausea, loss of appetite, high fever 
and headache. Prodromal symptoms and lesion pain are 
mild in children. The disease is more serious in adoles-
cents and adults and is particularly severe in subjects with 
immunological deficits due to HIV, leukemia or lympho-
ma, chemotherapy or steroid therapy for asthma or other 
diseases. It is self-healing and generally heals in one to 
two weeks. Complications are rare in healthy children but 
more common in immunodeficient infants, teenagers or 
adults. The most common complications are bacterial su-
perinfection of the pustules (5% of cases), laryngitis, pneu-
monia (1%), thrombocytopenia and neurological prob-
lems (1-3.5 every 100,000 children under 14 years). These 
are much more frequent in immunodepressed subjects 
and include encephalomyelitis, cerebellar ataxia, arthritis, 
hepatitis, haemorrhagic nephritis, myocarditis, and otitis 
media (Ellis et al., 2014; Galetta et al., 2015; Gershon and 
Gershon, 2013; Gershon et al., 2015; Moffat et al., 2007; 
Ouwendijk et al., 2015; Roderick et al., 2012).
Figure 1 - Schematic representation of the VZV life cycle. Infection takes place when the virus reaches the mucosal epi-
thelial sites and initiates local replication. This is followed by spread to tonsils and other regional lymphoid tissues. Here, 
VZV infects T cells and gives rise to a transient, low-grade viremia that delivers the virus to the reticular endothelial system 
for a second massive burst of replication. Through blood circulation, the infected T cells eventually transport the virus to the 
epidermal cells of the skin and mucous membranes. At these sites, VZV replicates causing the typical vesicular lesions and 
is released into droplets from the respiratory tract. Latency is established in innervating neurons. Immune responses to in-
fection immediately ensue. Interferon-α and -b (IFN) produced by resident skin cells and recruited dendritic cells are the first 
to appear in the circulation. Natural killer (NK) cells are also activated early in infection and presumably kill infected cells. 
The appearance of VZV-specific T cells coincides with the resolution of skin lesions and is accompanied by sharp increases 
in specific IgM and IgG.
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If the infection is contracted in the first two trimesters of 
pregnancy, VZV can be transmitted to the fetus causing the 
congenital varicella syndrome that occurs with skin scars, 
ocular defects, hypoplasia of the limbs and neurological 
alterations. Fetal damage often leads to miscarriage. Fe-
tuses exposed to VZV after the fifth month in utero may 
develop asymptomatic chickenpox and herpes zoster early 
in life. If the mother develops varicella five days before to 
two days after delivery, the newborn can exhibit a serious 
form of varicella with mortality rates close to 30% (Aro-
ra et al., 2017; Mandelbrot, 2012; Sauerbrei and Wutzler, 
2007).
Acquired immunity is permanent and reinfections are rare 
(Gershon and Gershon, 2013; Gershon et al., 2015; Wein-
berg and Levin, 2010). Despite a robust immune response, 
VZV is not eradicated but migrates from mucous and epi-
dermal lesions to sensory root ganglia or, in some instanc-
es, the cranial nerve where it remains latent throughout 
life and can reactivate to spread from the ganglion, via the 
sensory nerve root, to the innervated target tissue (skin, 
cornea, auditory canal, etc.) (Figure 1 and Figure 2).
Contrary to what was thought in the past, reactivations 
are frequent and occur subclinically in most cases. Con-
sequent viral replication and the resulting production of 
antigens recalls immune memory and maintains immu-
nity, thereby attenuating subsequent reactivations and al-
lowing the virus to “regenerate” by refreshing the pool of 
infected cells (Baird et al., 2013; Cohen, 2007; Gershon et 
al., 2012; Zerboni et al., 2014; Quinlivan and Breuer, 2014). 
Clinically evident reactivation, or zoster, takes place in 10-
20% of subjects who contracted the natural infection, with 
a likelihood of developing zoster increasing proportionally 
with age, especially after 50 years of age (Figure 2). Dur-
ing zoster, the virus crawls back to the dermis using nerve 
fibers that depart from the ganglion latency site. In the 
dermis and the epidermis, the virus establishes a new rep-
lication cycle with the appearance of clusters of vesicular 
lesions in the dermatome innervated by the nerve fiber, 
most commonly on the chest. Typically, a single dermat-
ome is involved, although two or three adjacent dermat-
omes may be affected. Lesions are accompanied by lo-
calized pain that, in some individuals, is so intense and 
prolonged to require the administration of local anesthet-
ics. In a number of cases, pain persists for over a month 
and is characterized by skin hypersensitivity (post-herpet-
ic neuralgia). The incidence of zoster varies, as said, with 
age: this is about 4.5 total individuals/1000. At 40-50 years, 
it affects 3 people out of 1000, while at 80 the incidence in-
creases to over 10 cases/1000 (Amjadi et al., 2017; Bennett 
and Watson, 2009; Chakravarty, 2017; Gershon et al., 2012; 
Giovanni et al., 2016; Johnson et al., 2015; Keating, 2016; 
Vrcek et al., 2017; Weaver, 2009; Yawn and Gilden, 2013).
Figure 2 - Reactivation of latent VZV and new encounters with the virus maintain immunity. Following acute infection, 
VZV persists in neurons and periodically reactivates. According to the Hope-Simpson hypothesis, subclinical reactivations of 
endogenous infection and occasional external contacts with varicella keep up immunity, here indicated by the red line, thus 
providing long-term protection against reinfection and clinically evident reactivation. Immunity, however, declines with age. 
In some people, periodic reactivation can fall below the critical threshold level of anti-VZV immunity indicated by the dotted 
grey line, and cause zoster. Vaccines to prevent zoster are designed to boost specific immunity to avoid reactivation from 
trespassing the critical threshold (modified from Gershon and Gershon, 2016).
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Immunity to VZV infection
Natural infection by VZV causes very early release of In-
terferon (IFN) type I in the blood stream, and IFN-α is 
also delivered locally to varicella lesions by plasmacytoid 
dendritic cells (Gerlini et al., 2006). It is very important, 
but not the key innate immune mechanism, as shown 
by the fact that mutations affecting its entity, such as in 
STAT-1, have not been associated with serious cases of 
varicella (Hambleton et al., 2013). NK cells can also be 
found early (Figure 1) (Arvin et al., 1986). Although direct 
evidence of the role exerted by NK cells during varicella 
is still lacking, clinical evidence suggests that this arm of 
immunity is crucial. NK cells and primed CD8+ T cells 
were nearly absent from the circulation during the early 
phase of life-threatening primary VZV infection (Bano-
vic et al., 2011; Vossen et al., 2005). In contrast, T lym-
phocyte responses to VZV are proven to be protective by 
several lines of evidence (Duncan and Hambleton, 2015). 
During varicella, T cell-mediated immunity is rarely de-
tected until skin lesions can be seen. The detection of T 
cells within three days after the appearance of the vari-
cella rash and rapid host response to primary VZV infec-
tion have long been known to be associated with mild-
er rash and more rapid clearance of viremia in healthy 
subjects (Arvin et al., 1986). Very recently, the ability of 
younger individuals to mount rapid cellular responses to 
VZV reactivation has been linked to protection against 
zoster (Weinberg et al., 2017). In addition, the entity of 
VZV-specific CD4+ T cell responses was shown to inverse-
ly correlate with both the severity of disease and viremia 
levels (Malavige et al., 2008). Conversely, the naturally 
occurring decrease in T cell immunity to VZV with age 
seems to be responsible for the occasional reactivation of 
VZV leading to zoster (Figure 2) (Miller, 1980; Levin et al., 
2003; Shirane et al., 2013). VZV-specific CD8+ T cells are 
also elicited during natural infection (Arvin et al., 1986). 
They exert an important protective role, as in other vi-
ral infections, but their role in recovery is controversial 
(Barton et al., 2012; Vossen et al., 2005). Recent work has 
correlated the levels of dysfunctional, exhausted CD8+ T 
cells in the elderly to the inability to mount an effective 
and timely response to VZV causing appearance of zoster 
(Weinberg et al., 2017).
VZV infection induces robust humoral (IgM, IgG, and 
IgA) in addition to cellular-mediated immunological re-
sponses (Figure 1). Antibodies persist for a lifetime and 
are believed to provide protection from possible reinfec-
tions, as proven by the protective effect of VZV-specific 
seroprophylaxis (Morell and Barandun, 1988). However, 
the early production of IgG or IgM does not seem to corre-
late with the severity of primary clinical infection or with 
the appearance of zoster (Arvin et al., 1986; Duncan and 
Hambleton, 2015). However, their rise after vaccination 
has been found to be an excellent marker for protection 
against zoster recurrent infection (Gilbert et al., 2014).
Immune responses, elicited by the attenuated VZV Oka 
vaccine strain, are thought to be qualitatively similar to 
the ones induced by the wild type strain, although on a 
smaller scale, because the viruses only differ by very few 
mutations (Quinlivan et al., 2014).
Laboratory diagnosis and therapy
Diagnosis is often performed only on a clinical basis but 
laboratory tests are still essential and used routinely in 
cases of disseminated infection and in atypical cases. The 
virus is usually searched for by molecular tests, on skin 
lesion fluid, or cerebrospinal fluid in the case of central 
nervous system involvement. Sometimes the analysis is 
extended to blood and respiratory samples. Serologic di-
agnosis is useful to identify unprotected individuals and 
to distinguish primary infection from reactivation. The 
co-presence of IgM and IgG is indicative of recent infec-
tion or vaccination. The presence of IgG only indicates 
previous exposure and immunity from reinfection (Ger-
shon et al., 2015; Heininger and Seward, 2006; Mandel-
brot, 2012; Sauerbrei, 2016). The absence of antibodies 
does not exclude infection by VZV both because they be-
gin to be detectable by the time of rash appearance and 
because false-negative and false-positive results for IgM 
and false-negative results for IgG have been reported us-
ing validated commercial diagnostic systems (Kinno et al., 
2015; Wiese-Posselt et al., 2017). In cases of suspected in-
fection and in the presence of negative serological tests, 
the subject should be retested for antibodies within two 
to three weeks.
Therapy is generally only symptomatic. In children at 
risk of complications and, in general, in adolescents and 
adults, intravenous or oral administration of antiherpetic 
agents, such as acyclovir and derivatives (valacyclovir and 
famcyclovir), can be used. In some HIV-positive patients, 
the emergence of VZV strains resistant to acyclovir has 
been reported. These subjects had been treated with the 
drug for protracted periods of time, plausibly favoring the 
selection of viral variants defective or mutant for thymi-
dine kinase, the viral enzyme necessary for the activation 
- by phosphorylation - of acyclovir. A drug active against 
acyclovir-resistant VZV is Foscarnet, an analogue of py-
rophosphate also used against cytomegalovirus and HSV. 
Foscarnet does not require phosphorylation (Abendroth et 
al., 2010; Gérard and Salmon-Céron, 1995; Gershon and 
Gershon, 2013; Schuster et al., 2016).
Immunotherapy is an effective alternative to chemother-
apy and is used for the subjects listed in Table 1. Purified 
immunoglobulins or hyperimmune sera containing specif-
ic anti-VZV antibodies are administered intramuscularly 
within 96 hours and up to 10 days after the appearance 
of rash. After this period, the efficacy of immunoglobulins 
wanes, though this is not yet fully demonstrated (Garrub-
ba and Donkers, 2013; Kim et al., 2014; Marin et al., 2013).
Epidemiology
Varicella was very common before the introduction of 
vaccination. Today, also due to poor vaccine coverage, it 
Table 1 - Subjects for whom administration of anti-VZV im-
munoglobulin is recommended (adapted from Marin et al., 
2013).
Immunocompromised subjects with no specific anti-VZV im-
munity
Newborn infants from mothers who show signs and symptoms 
of varicella within 5 days before to 2 days after delivery
Hospitalized premature infants born at >28 weeks of gestation 
whose mothers do not exhibit specific immunity
Hospitalized newborns born at <28 weeks of gestation, wei-
ghing less than 1 Kg at birth, independently of the mother’s 
immune status
Pregnant women with no evidence of immunity against VZV 
and diagnosed with recent VZV infection
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is the most widespread rash illness in Italy. In the Unit-
ed States, there were about 4 million cases (about 1600 
cases per 100,000 inhabitants), 11,000-13,000 cases of 
hospitalization and 100-150 deaths per year in the early 
1990s (Amjadi et al., 2017, Wharton, 1996; Yawn and Gild-
en, 2013). With the introduction of vaccination in 1995, 
the number of cases decreased by 79% in the 2000-2010 
period compared to the pre-vaccination era and, since the 
introduction of a second vaccine dose, by 93% in 2012. In 
the same year, hospital admissions and deaths from var-
icella decreased by 90%. The spectacular reduction rate 
is due to an effective vaccine policy, which also allowed 
the rapid establishment of herd immunity: in the period 
2010-2015, 90% of children between 19 and 35 months 
received a vaccine dose (83-95% in individual states); the 
same levels were reached among adolescents, of whom 
80% received two doses of vaccine (CDC, 2017; Nguyen et 
al., 2005). Compared to the US, the situation is much more 
heterogeneous in the 38 countries of the European Union: 
vaccination began ten years later and follows policies that 
differ from country to country. It is part of the routine vac-
cination program in three countries (Germany started in 
2004, Greece in 2006, and Latvia in 2008), in a few regions 
of Italy (Sicily since 2003, Veneto since 2007, Apulia and 
Tuscany since 2010), and in certain autonomous regions 
of Spain (since 2006-2009), while it is recommended only 
for individuals at risk and immunocompromised patients 
in 17 countries (including Italy and Spain for the regions 
not mentioned above). There is no policy for the other 12 
nations (Paganino et al., 2015).
Different surveillance systems (non-existing in some 
states) and clinical case definitions make it difficult to 
have a clear picture of varicella incidence and complica-
tions. In one of the most comprehensive reports signed 
by the European Network for monitoring vaccine-pre-
ventable diseases (EUVAC.NET), about 5,500,000 cases 
of varicella were reported for the period 2000-2007 in 
the 15 countries with mandatory notification. This cor-
responds to an average of about 320 cases per 100,000 
inhabitants. The lower incidence found compared to the 
United States is accounted for by a different policy in 
reporting cases: for example, in the period 2000-2007, 
Spain reported twice as many cases as Italy and Poland 
and over four times as many as states with no obligation 
to notify. Regardless of the number of cases reported, the 
incidence was greater in the ages of 1-4 years, as expect-
ed (2588 cases/100,000) and 4-9 years (1943/100,000) (de 
Boer et al., 2014; EUVAC.NET, 2010; Helmuth et al., 2015; 
Marin et al., 2008; Paganino et al., 2015; Yawn and Gild-
en, 2013).
According to data collected by the SPES network (Sorveg-
lianza PEdiatri Sentinella) of the Italian National Health 
Institute (ISS), varicella has been the most frequent in-
fectious disease in Italy, with an average of about 105,000 
cases/year from 1996 to 2004. Since then, also thanks to 
the vaccination policy introduced in some regions, the 
number of cases has been steadily falling from almost 
98,000 cases of 2006 to 60,000 in 2009. The main peaks 
of incidence were observed over the period March to May 
and December without any significant differences by ge-
ographical area. The most heavily affected age group is 
between 1 and 4 years of age, with an incidence of 7300 
cases per 100,000 inhabitants, 1377/100,000 in the 5-14 
age range in 2004, the year when the highest number of 
cases was recorded (de Boer et al., 2014; ISS, 2017a).
Current and future vaccination strategies
History of the development of a successful  
vaccine strain
The observation that specific immune defenses devel-
oped following natural infection give lifelong immunity 
to subsequent reinfections suggested the idea that a vac-
cine could be obtained against VZV. In the mid-1960s, 
due to the extraordinary results achieved with vaccines 
against poliovirus and the fact that the spread of varicella 
was such that, for example in Japan, there were similar 
number of cases and births per year (Ozaki and Asano, 
2016), a competition started between states for the pro-
duction of a vaccine. At present, all vaccine strains have 
so far been derived from the one obtained in 1971, in Ja-
pan, by Dr Michiaki Takahashi who was the first person 
in the world to obtain a live and attenuated strain derived 
from the wild virus isolated from the vesicle fluid of an 
infant with varicella. The strain was named Oka from the 
surname of the child’s family, a choice that today would 
not be deemed appropriate for ethical and legal issues. 
Attenuation was obtained with the traditional serial 
propagation scheme in non-human cell cultures. Since it 
is highly species-specific, VZV replicates only in human 
and monkey cells. The parental strain of Oka, however, 
showed a modest initial replication activity in embryonic 
guinea pig cells. Adaptation to these cells took place fol-
lowing isolation and propagation of the parental strain 
in human lung embryonic cells cultured at 34ºC. The vac-
cine stock was then generated with 12 passages in guinea 
pig cells followed by other short passages in WI-38 and 
MRC-5 (diploid human cells).
Oka was used for the first time in 1974 in a Japanese clinic 
to successfully protect 23 children from varicella trans-
mission by a child admitted to the same pediatric ward 
(Takahashi et al., 1974). The vaccine, licensed by the Jap-
anese firm Biken, was subsequently approved for use on 
high-risk leukemic children, again in Japan, (Gershon and 
Gershon, 2013), then for healthy children in Japan and 
Korea in 1989 and was finally approved for children over 
12 months of age by the FDA in 1995 (Arnould and Mes-
saoudi 2017; Ozaki and Asano, 2016).
Among anti-VZV vaccines derived from Oka and mar-
keted today, the most common are: the live attenuated, 
monovalent vaccines Varivax, Varilrix and Zostavax; the 
live attenuated, tetravalent vaccines Proquad and Pri-
orix-Tetra that also immunize against measles, mumps, 
and rubella. Other vaccines comprise the subunit vaccine 
Shingrix (or HZ/su, recently approved), the heat-inacti-
vated vaccine V212 (in advanced phase of experimen-
tation), and a few others under preclinical testing. Vac-
cinal preparations already in use for mass vaccination 
or in the pipeline will be described individually in the 
following chapters. For the sake of simplicity and ease 
of comparison, Table 2 shows their main advantages and 
disadvantages.
The molecular mechanisms that led to Oka attenuation 
are not yet well defined. It is known that its propagation 
on non-human cell lines has caused the accumulation 
of mutations along the genome, as expected, but lack of 
an animal model and genetic heterogeneity of vaccine 
preparations have hitherto prevented the definition of 
the contribution of individual mutations to the atten-
uated phenotype (Quinlivan et al., 2011; Quinlivan and 
Breuer, 2014). Despite this, over 100 million doses of Oka 
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have been administered, resulting in a dramatic fall in 
the incidence and mortality of VZV infection with very 
few adverse effects.
LIVE ATTENUATED VACCINES
Efficacy, effectiveness and duration  
of immune response
Live attenuated anti-VZV vaccines are excellent immuno-
gens, therefore they all show high efficacy, defined as the 
ability to yield an immune response. Retrospective studies 
carried out on hundreds of thousands of subjects demon-
strate that these vaccines induce antibody and cell-mediat-
ed response in over 95% of subjects. As far as effectiveness 
is concerned, or their capability of protecting against the 
disease, rates between 50 and 70% in reducing the risk of 
developing clinical manifestation of zoster have been re-
ported, with differences depending mainly on the age of 
subjects. Regarding duration of the immune response, this 
has been seen to decline over the years, but remains at a 
protective level against zoster 10 years after vaccination. To 
obtain a long-lasting protective effect, two distant vaccine 
doses are recommended and now adopted by most sched-
ules in many countries (Ansaldi et al., 2016; Bennett and 
Watson, 2009; de Boer et al., 2014; Helmuth et al., 2015; 
Skull and Wang, 2001; Vrcek et al., 2001; Wang et al., 2016).
Live attenuated VZV vaccine is not recommended in sub-
jects with primary or acquired immunodeficiency (Table 2) 
because of the risk of developing zoster within 4-6 weeks 
of vaccination (Maggi et al., 2015; Marin et al., 2013; Ox-
man and Schmader, 2014). However, given the high inci-
dence of zoster and its complications, vaccination of sub-
jects with immunological disorders is often performed in 
clinical practice, offering some benefit. In this case, effica-
cy and effectiveness are expected to be reduced compared 
to immunocompetent subjects but are still significant: 
reduction of the risk of developing clinical manifestation 
of zoster ranges between 35 and 45% in several studies, 
depending on the age and immunological dysfunction of 
subjects (Ansaldi et al., 2016; Chakravarty, 2017; Garru-
ba and Donkers, 2013; Giovanni et al., 2016; Hardy et al., 
1991; Wang et al., 2016).
Tolerability and adverse reactions to vaccination
Again, studies have been carried out on very sizeable co-
horts. In most cases, only transient adverse effects to vac-
cination have been reported. The most common is the on-
set of a skin rash of variable extension within one month 
of vaccination, which heals spontaneously without signifi-
cant sequelae. Other cases report pain, redness, and swell-
ing at the inoculum site. Most studies report an incidence 
of adverse effects ranging from 2 to 4 per 10,000 vaccine 
doses. Case-control studies did not find any significant-
ly increased risk of exacerbation or induction of diseas-
es such as systemic lupus erythematosus, Guillain-Barré 
syndrome, multiple sclerosis, neuritis, thrombocytopenia, 
or vasculitis. The most serious adverse effects are those 
involving the central nervous system, symptoms of which 
may vary and include aseptic meningitis and cerebellar 
ataxia. These are, however, very rare: one of the most com-
prehensive systematic studies reports 30 neurological ad-
verse effect cases out of 16,683 adverse events reported. In 
none of these, however, was the vaccine strain found in the 
cerebrospinal fluid of subjects (Flatt and Breuer, 2012). In 
general, therefore, the vaccines are well-tolerated with a 
low risk of mild to moderate adverse effects and very rare 
severe adverse reactions (Ansaldi et al., 2016; Arnold & 
Messaoudi, 2017; De Boer et al., 2014; Flatt and Breuer, 
2012; Hardy et al., 1991; Johnson et al., 1997; Marin et al., 
2008; Wang et al., 2016).
Table 2 - Pros and cons of live attenuated, inactivated or subunit vaccines against VZV.
Vaccine Pros Cons
Live, attenuated
Varivax, Varilrix, 
Zostavax, ProQuada  
and Priorix-Tetra
Stimulate both cellular and humoral 
immune response
Not recommended for subjects who are immunosuppressed 
due to chemotherapy, radiotherapy, steroids, neoplastic 
diseases, etc.
Long-lasting immune protection Not recommended for subjects who are immunosuppressed 
genetically or due to acquired diseases (HIV, tuberculosis) 
Immune response stimulated by 
spontaneous reactivation of vaccine strain
Risk of shedding and transmitting vaccine strain to 
immunodepressed subjects
Cold chain integrity needs to be preserved in order to 
maintain infectivity
Not recommended for pregnant women. Pregnancy should 
be avoided in the 3 months following vaccination.
Immunity and effectiveness tend to wane over time after 
vaccination.
Heat-inactivated
V212 Safe in immunodepressed subjects Stimulates lower and less efficient immune response 
compared to live attenuated vaccines
Does not require maintenance of cold 
chain integrity 
Requires 4 doses for protective immunity, complicating 
compliance
Subunit
Shingrix Contains only one viral protein High incidence of adverse events
Safe in immunodepressed subjects
aFor tetravalent attenuated vaccines (containing also measles, mumps and rubella attenuated strains), only aspects relative to VZV are discussed.
Varicella-zoster virus: pathogenesis, clinical picture, and vaccination 101
Persistence and reactivation of the vaccine virus
VZV Oka causes an infection that is promptly contained 
by the immune system and, like the wild virus, subse-
quently persists in the ganglia in a latent state (Gershon 
et al., 2012; Kennedy et al., 2015; Quinlivan and Breuer, 
2014). Reactivation occurs periodically, almost always si-
lently and only rarely in a clinically manifest way (Ansaldi 
et al., 2016; Arnould and Messaoudi, 2017; de Boer et al., 
2014; Skull and Wang, 2001). Reactivation is, on the one 
hand, beneficial because it boosts immunological mem-
ory (Figure 2). On the other hand, it is a reason for con-
cern because it could cause zoster even at a young age 
(Brunell and Argaw, 2000; Cimolai et al., 2014; Schmid 
and Jumaan, 2010). It has also been argued that zoster 
from Oka may occur more frequently in old age due to 
aging of the immune system (Figure 2) (Baxter et al., 2013; 
Cohen, 2007; Gagliardi et al., 2016; Gershon et al., 2015; 
Gershon and Gershon, 2016; Krause and Klinman, 1995; 
Weaver, 2009). For this reason, in some countries, such 
as Great Britain, vaccination against VZV is not includ-
ed among pediatric vaccines and is only offered to people 
at risk of contracting varicella and developing complica-
tions (Ansaldi et al., 2016; Gershon and Gershon, 2016). 
Recently, however, these concerns have been proven to be 
unfounded, because prospective studies in Japan, South 
Korea, Europe and the United States have shown that chil-
dren vaccinated in the ’70s and ’90s have a lower risk of de-
veloping zoster than those who contracted the natural in-
fection (Sadzot-Delvaux et al., 2008; Schmid and Jumaan, 
2010). Another recent study shows that the incidence of 
zoster in vaccinated subjects between 0 and 17 years of 
age was 79% lower than in subjects of the same age infect-
ed with wild-type VZV (Weinmann et al., 2013). The same 
protective effect is obtained in subjects with reduced im-
mune efficiency: a study on children with leukemia shows 
that the incidence of zoster after vaccination is 67% lower 
than in leukemic children who contracted natural infec-
tion (Hardy et al., 1991).
Interference with vaccination
In addition to constitutive or occasional host factors dis-
cussed for each individual vaccine, common interfering 
factors for all anti-VZV vaccines are the presence of ma-
ternal anti-VZV antibodies and close vaccination with the 
measles-mumps-rubella vaccine (MMR). If anti-VZV vac-
cination is performed less than 30 days after MMR, sub-
jects have a threefold higher risk of developing chickenpox 
compared to subjects of the same age in which the two 
vaccines were administered more than 30 days apart from 
each other. The reasons for such reduction in efficacy are 
not fully understood. It may be a combined effect of inter-
fering antibodies induced by other immunogens, produc-
tion of interferon and other molecules with antiviral activ-
ity (Verstraeten et al., 2003), or a reduced responsiveness 
of the immune system to mitogens and antigens caused 
by measles infection (Karp et al., 1996; Mina et al., 2015). 
Conversely, the four attenuated vaccines administered at 
the same time do not interfere with each other as far as in-
duction of immunity against VZV is concerned (Lapphra 
and Scheifele, 2009).
Varivax and Varilrix
Varivax is produced by Merck, Sharp & Dohme (MSD). 
The preparation, also known as Oka/MSD, was produced 
by propagating the original the Oka strain for another 31 
passages in MRC-5 cells, then lyophilized. The preparation 
is resuspended in water before use. Varivax was the first to 
be approved: it was used in 1988 in Japan and Korea to 
vaccinate children from 12 months of age, then in 1995 in 
USA and in some European states for an analogous sub-
ject group. It is administered by subcutaneous injection 
in two doses, the first at 12-15 months, the second at 4-6 
years. The latter can be administered from three months 
to over 13 years after the first dose. For unvaccinated ad-
olescents, the two doses must be administered one to two 
months apart from each other (Marin et al., 2008; Wang 
et al., 2016).
Varilrix is marketed by GlaxoSmithKline (GSK), United 
Kingdom, Biken, Japan, and Changchun BCHT Biotech-
nology, China, and has a similar composition to Varivax 
and therefore it shares its mode of administration. Both 
have proven to be well-tolerated and highly immunogenic, 
with 97% children exhibiting antibodies when tested 7-10 
years after vaccination (Johnson et al., 1997). The effec-
tiveness of the vaccine is 70-90% in protecting from infec-
tion and 90-100% in reducing severity of disease (Baxter et 
al., 2013; Krause and Klinman, 1995). In 78% adolescents 
and adults, antibodies develop after the first dose, while 
99% have antibodies after the second administration at 
four weeks (Ansaldi et al., 2016; Baxter et al., 2013; Krause 
and Klinman, 1995). 
There are subjects who become infected with wild-type 
virus despite vaccination (breakthrough varicella). A re-
cent review systematically examined 34 studies published 
from 1974 to 2016 reporting sixty such cases: most were 
mild, some required hospitalization for the involvement 
of various organs and six were fatal. Considering that 
each year more than 30 million doses are distributed, the 
risk of breakthrough varicella is very low (Leung et al., 
2017). Among its causes are exposure to wild-type virus 
before the vaccine is able to induce a protective immune 
response and the existence of factors that interfere with 
vaccinal infection and/or the induction of the immune 
response. Among them, the most common are: asthma, 
use of steroids, vaccination when less than 15 months old, 
errors in storage and administration of the vaccine and, 
as described above, vaccination against MMR less than 
30 days prior to VZV vaccination (Gershon and Gershon, 
2016; Lapphra and Scheifele, 2009; Verstraeten et al., 
2003; Wang et al., 2016).
Zostavax
Zostavax consists of a lyophilized preparation of the live 
Oka/MSD attenuated strain grown on MRC-5 human cells. 
It contains at least 19,400 plaque forming units (PFU)/dose 
against the 1,350 PFU of Varivax. It was conceived and 
approved by the FDA for the prevention of zoster in 2006 
(Oxman et al., 2005, Levin, 2012). The initial study led to 
its approval, while subsequent larger studies showed that 
zoster risk is reduced by over 65% in subjects aged 50-59 
years, about 50% in subjects aged 60-69 years and, in this 
group, post-herpetic neuralgia is prevented by 66.5% for 
those subjects in whom zoster does show up. In subjects 
over 70, effectiveness is reduced by roughly 37% as con-
cerns zoster (Ansaldi et al., 2016; Arnould and Messaoudi, 
2017; Gagliardi et al., 2016).
Although it is not recommended and largely ineffective 
in immunocompromised subjects, Zostavax did show 
some clinical benefit without serious side-effects in these 
patients (Del Giudice et al., 2015; Flatt and Breuer, 2012; 
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Gagliardi et al., 2016). Unfortunately, also due to the age 
of the vaccinated subjects, induced immunity is of limit-
ed duration, causing protection rates to fall to 20-30% 7 
to 10 years after vaccination (Cook and Flaherty, 2015). 
The decrease in vaccine effectiveness is mainly due to the 
rapid decline in cell-mediated responses, which is funda-
mental to the restriction of reactivation. In these subjects, 
this is reduced by 40-50% one year after vaccination and 
returns to pre-vaccination levels after three years (Oxman 
et al., 2005). A 10-year recall from the first dose is there-
fore necessary and recommended to protect individuals 
over 70 years from zoster (Levin et al., 2003; Oxman et al., 
2005). The recall dose increases cell-mediated responses 
transiently and by levels inversely proportional to the age 
of the subject; the antibody response increases as well but 
also not as greatly as after natural reactivation (Arnould 
and Messaoudi, 2017). Notably, Zostavax-induced cell-me-
diated response cross-reacts with HSV antigens, probably 
leading to some degree of protection against the latter vi-
rus as well (Jing et al., 2016). The vaccine is well tolerated 
and does not bring about significant adverse effects, even 
in older subjects (Del Giudice et al., 2015; Flatt and Breuer, 
2012; Gagliardi et al., 2016; Levin, 2012).
ProQuad and Priorix-Tetra
ProQuad and Priorix-Tetra are made up of attenuated 
MMR combined with Oka and are produced, respec-
tively, by MSD and GSK. They were approved in 2006 to 
vaccinate children 12 months to 12 years old with two 
doses, and are employed in the USA, Australia, Canada 
and various European countries (Marin et al., 2010; Pry-
mula et al., 2014). ProQuad and Priorix-Tetra have the 
same MMR strains and titers of trivalent formulation 
but contain four and seven times more OKA compared 
to Varivax, respectively. The efficacy and immunogenicity 
of ProQuad and Priorix-Tetra against VZV are compara-
ble to monovalent vaccines, while they are more likely 
to cause fever and measles-rubella rash than MMR (Le-
ung et al., 2015). Fever attacks are infrequent and are not 
associated with long-term problems (Arnould and Mes-
saoudi, 2017; Flatt and Breuer, 2012). To reduce the risk 
of fever attacks, CDC recommends administering a first 
dose of MMR and Oka separately, at the same time but 
at different body sites, and a second dose of tetravalent 
vaccine (Marin et al., 2010).
INACTIVATED VACCINES
V212
V212 is substantially the heat-inactivated version of 
Varivax and is recommended for the immunization of 
subjects with severe immunodepression, such as hemato-
poietic stem cell and bone marrow transplant patients 
(Hata et al., 2002; Redman et al., 1997). The first phase I 
and II studies showed good tolerability in young and im-
munocompetent subjects. A randomized, double-blind, 
MSD-funded study was completed in July 2017 and eval-
uated the safety and efficacy of the candidate vaccine in 
subjects with solid or hematologic cancer over a five-year 
period (Clinical trial No. NCT01254630, www.clinicaltri-
al.gov). The enrollment of patients started at the end of 
2010 and the study estimated the incidence of zoster in 
1000 patients per year over the study period and the ap-
pearance of adverse effects from day 1 to day 28 of vacci-
nation for the four doses included in the vaccine protocol 
(Table 2). The results are being evaluated and are not yet 
available but, given the good outcome in phase I and II 
studies, it is likely that V212 will prove to be effective 
and therefore suitable to vaccinate subjects for whom the 
attenuated VZV vaccines described above are not recom-
mended.
SUBUNIT VACCINES
Shingrix
Shingrix, or HZ/su, is a subunit vaccine made up of the 
VZV envelope glycoprotein E (gE). This vaccine is pro-
duced by GSK and has been approved in US and Canada 
in October 2017, and more recently, in Europe and Japan, 
for the prevention of shingles in adults over 50 years of age 
(EC for Public Health, 2018; FDA, 2017).
VZV gE was chosen as an immunogen because it is the 
most abundant viral glycoprotein produced by infected 
cells and is one of the main targets of the immune system 
for the production of both specific antibodies and CD4+ T 
cell responses (Abendroth et al., 2010; Moffat et al., 2007; 
Weinberg and Levin, 2010). In the vaccine formulation, gE 
is a recombinant protein deleted of its membrane anchor 
and carboxy terminal domains produced in Chinese ham-
ster ovary cells (Haumont et al., 1996). To increase its effi-
cacy at inducing cell-mediated responses, gE is combined 
with AS01B, a liposome-based adjuvant consisting of a 
mixture of MPL (3-O-desacyl-4’-monoophosphoryl lipid 
A) and saponin QS-21, extracted from the plant Quillaja 
saponaria. MPL is a Toll-like receptor-4 agonist, whereas 
QS-21 increases the absorption and retention of antigen 
by dendritic cells (Coffman et al., 2010; Lal et al., 2013). 
A dose of Shingrix contains 50 μg of gE mixed in 100 μg 
AS01B (50 μg MPL and 50 μg QS-21). The vaccine sched-
ule is two doses inoculated in the deltoid.
In phase I and II studies carried out on adult and elderly 
subjects, HZ/su showed excellent immunogenicity profiles: 
two doses of HZ/su vaccine induced antibody and cell-me-
diated responses against gE and VZV lysate higher than 
those induced by two doses of Varilrix in subjects of 50-70 
years of age during a one-year follow-up. As with other 
vaccines, specific immune responses gradually decreased 
to half 42 months from vaccination (Leroux-Roels et al., 
2012). Three doses of HZ/su administered to hematopoiet-
ic cell transplant or HIV-positive patients proved to be im-
munogenic and did not cause major side-effects (Berkow-
itz et al., 2015; Stadtmauer et al., 2014). The product was 
also tested in two phase-III studies, named ZOE-50 and 
ZOE-70. The first involved over 15,000 subjects aged 50 di-
vided into vaccine and placebo groups that were followed 
for over three years. The efficacy of the vaccine was 97.2% 
with a zoster incidence of 0.3/1,000 people/year in vaccine 
versus placebo 9.1 (Lal et al., 2015). 
In ZOE-70, 13,900 subjects with an average age of 75.6 
years were enrolled, divided into two equal groups and fol-
lowed for 3.7 years. In the vaccine group, the efficacy was 
89.8%, with very few differences between subjects under 
and over eighty years. As in ZOE-50, the risk of zoster was 
considerably reduced in the vaccine group compared to 
the placebo group (0.9 vs. 9.2/1000 people/year) (Cunning-
ham et al., 2016; Cunningham and Heineman, 2017).
The very good news has been offset by the incidence of 
adverse effects: in ZOE-50, 85.1% of vaccinees reported 
solicited local symptoms (pain, redness and swelling) at 
the injection site, 66% reported solicited systemic symp-
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toms (fatigue, fever, gastrointestinal symptoms, headache 
and myalgia) and 11.4% of subjects over 50 years of age 
reported solicited systemic symptoms of grade 3, defined 
as significant pain that prevented normal daily activity 
(Arnold and Messaoudi, 2017; Lai et al., 2015).
CONCLUSIONS
The pathway VZV takes to replicate and spread within the 
host organism, how it persists and the multifarious clini-
cal manifestations induced by primary infection and re-
activation make the virus an extremely interesting model, 
also from a microbiological point of view. Oka, the attenu-
ated strain and founder of today’s VZV vaccines, is no less 
interesting. The mutations and the molecular mechanisms 
that have led to a marked change in phenotype are not 
known but attenuation is quite stable, millions of individ-
uals have been vaccinated with the Oka strain with mini-
mal adverse effects and no reversion to the wild phenotype 
has been reported.
Unfortunately, VZV does not raise the same interest as 
regards public health. Varicella is considered a benign 
disease with no sequelae provided that the immune sys-
tem is functional and efficient and the infection is con-
tracted at school age. However, the age of encounter with 
varicella and the average age of the Western population 
is rapidly rising, and so is the risk of developing zoster, 
which is painful and not easy to control, even therapeu-
tically. From this point of view, the VZV vaccine policies 
adopted by many countries are hard to agree with. It-
aly is perhaps the most obvious example where, due to 
a curiously disparate regional policy, there are regions 
where vaccination coverage is down to an embarrassing 
10% and others where it is close to 80%. Even the latter 
figure is, in any case, far from the goals of the recently 
announced National Vaccine Plan (ISS, 2017b). Hopeful-
ly, the release of inactivated vaccines for older people and 
greater awareness of the mid- to long-term consequences 
of primary infection will favor wider vaccine coverage 
also for VZV. This will help varicella infection no longer 
be the leader in the disgraceful list of the most common 
rash infections in childhood.
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